feed,title,long_url,short_url
Benzinga,"Purple Biotech's Assets Are First In Class For Solid Tumor Treatment, Analyst Says",https://benzinga.com/general/biotech/22/10/29292976/purple-biotechs-assets-are-first-in-class-for-solid-tumor-treatment-analyst-says,https://bit.ly/3MECfum
Benzinga,Credit Suisse Sees Boston Beer's Q3 Margins Improving On Pricing Benefits,https://benzinga.com/analyst-ratings/analyst-color/22/10/29292847/credit-suisse-sees-boston-beers-q3-margins-improving-on-pricing-benefits,https://bit.ly/3VznHQB
Benzinga,Cano Health Stock Plummets As CVS Health Abandons Buyout,https://benzinga.com/m-a/22/10/29293230/cano-health-stock-plummets-as-cvs-health-abandons-buyout,https://bit.ly/3gfqbU2
